Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin

What happened

Pelthos Therapeutics and Castle Creek Biosciences have signed a definitive agreement for Castle Creek to merge with Pelthos. The combined company will operate as Pelthos Therapeutics and continue trading on the NYSE American under the ticker PTHS.

Confirmed

Global impact / market context

The deal pairs Castle Creek's late-stage fibroblast-based cell and gene therapy work with Pelthos' approved dermatology products and commercial reach. That could let the combined company develop and sell skin-disease treatments more efficiently, though the merger still must close before any of this happens.

Analyst inference

Pelthos investors are weighing a combination that adds an experimental rare-disease gene therapy to an existing commercial business. If completed, the company's spending priorities and cash needs could shift toward late-stage trials and manufacturing for redosable gene therapies, which means treatments given more than once.

Analyst inference

What to watch

1. The companies announced a definitive agreement under which Castle Creek will merge with Pelthos, with the combined company keeping the Pelthos name and the PTHS ticker on the NYSE American. Confirmed
2. Watch whether Pelthos details how it will fund Castle Creek's late-stage D-Fi program, including possible new shares or borrowed money, which means debt, before the merger closes. Proposed
3. Track progress of Castle Creek's lead candidate D-Fi, an injectable redosable gene therapy for dystrophic epidermolysis bullosa, a rare skin-blistering disease, since trial delays could raise costs for the combined company. Analyst inference

Evidence

• globenewswire.com